- Home
- RC vs RLAY Comparison
RC vs RLAY Comparison
Compare RC & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RC
- RLAY
- Stock Information
- Founded
- RC 2007
- RLAY 2015
- Country
- RC United States
- RLAY United States
- Employees
- RC N/A
- RLAY N/A
- Industry
- RC Real Estate Investment Trusts
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RC Real Estate
- RLAY Health Care
- Exchange
- RC Nasdaq
- RLAY Nasdaq
- Market Cap
- RC 755.3M
- RLAY 610.3M
- IPO Year
- RC N/A
- RLAY 2020
- Fundamental
- Price
- RC $3.72
- RLAY $3.41
- Analyst Decision
- RC Hold
- RLAY Strong Buy
- Analyst Count
- RC 6
- RLAY 12
- Target Price
- RC $6.54
- RLAY $18.45
- AVG Volume (30 Days)
- RC 1.9M
- RLAY 2.1M
- Earning Date
- RC 08-07-2025
- RLAY 08-07-2025
- Dividend Yield
- RC 13.48%
- RLAY N/A
- EPS Growth
- RC N/A
- RLAY N/A
- EPS
- RC N/A
- RLAY N/A
- Revenue
- RC N/A
- RLAY $8,355,000.00
- Revenue This Year
- RC N/A
- RLAY $17.59
- Revenue Next Year
- RC $50.48
- RLAY N/A
- P/E Ratio
- RC N/A
- RLAY N/A
- Revenue Growth
- RC N/A
- RLAY N/A
- 52 Week Low
- RC $3.71
- RLAY $1.78
- 52 Week High
- RC $8.64
- RLAY $10.72
- Technical
- Relative Strength Index (RSI)
- RC 32.26
- RLAY 47.37
- Support Level
- RC $3.80
- RLAY $3.31
- Resistance Level
- RC $3.90
- RLAY $3.65
- Average True Range (ATR)
- RC 0.13
- RLAY 0.19
- MACD
- RC -0.02
- RLAY -0.01
- Stochastic Oscillator
- RC 2.63
- RLAY 53.85
About RC Ready Capital Corproation
Ready Capital Corp is a real estate finance company. It acquires, manages, originates, and finances small-balance commercial loans to purchase small multi-family, office, retail, mixed-use, or warehouse properties. The company's segments consist of LMM Commercial Real Estate and Small Business Lending. It generates the majority of its revenue from LMM Commercial Real Estate.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).